GET DAILY SIGNALSActinium Pharmaceuticals (ATNM) Climbs +32% on Early Clinical Data Momentum
Key Takeaways
- ATNM shares rose roughly +32% over the trailing 30 days, climbing from about $1.08 to $1.43.
- The rally was driven primarily by first-in-human Phase 1 data for ATNM-400 in prostate cancer presented at EANM 2026, alongside supportive preclinical pan-tumor results.
- Over the trailing quarter, the stock has advanced roughly +79% from around $0.80 in early August.
- Wall Street analysts reiterated Buy ratings with price targets ranging from $3.00 to $5.00 following the data readout.
- Additional catalysts include the ASH 2026 Actimab-A abstract and the NYSE American compliance-plan extension through November 2027.
- For deeper context on valuation and upcoming catalysts, explore Actinium Pharmaceuticals' Price Targets, Earnings, and Forecast pages.
- Investors tracking momentum and AI-driven strategies can also explore Trending AI Robots for additional market insight.
Company Overview and Market Position
Actinium Pharmaceuticals is a clinical-stage biopharmaceutical company focused on targeted radiotherapies, or radioconjugates, that deliver high-energy alpha-particle radiation from Actinium-225 straight to cancer cells. The approach is designed to maximize tumor-killing power while limiting harm to surrounding healthy tissue.
The pipeline centers on three main areas: solid tumor programs led by ATNM-400, a first-in-class HER3-targeted Actinium-225 radiotherapy; Actimab-A, a CD33-targeting candidate developed for acute myeloid leukemia and myelodysplastic syndrome under a Cooperative Research and Development Agreement with the National Cancer Institute; and targeted conditioning agents such as Iomab-B for bone marrow transplant and Iomab-ACT for cell and gene therapies. The company stands out for its non-PSMA approach in radiopharmaceuticals and holds a patent estate of roughly 250 issued and pending patents worldwide. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Stock Price Performance Over the Last 30 Days and Quarter
Over the trailing 30 days, ATNM advanced approximately +32%, rising from a closing price near $1.08 in early October to $1.43. The move was not entirely linear, with shares surging around the mid-October EANM 2026 data presentations, experiencing a brief pullback, and then recovering into early November.
The quarterly view shows even stronger gains. In early August, ATNM traded near $0.80, and the stock has since climbed roughly +79%. This reflects a sustained repricing as the company delivered multiple clinical and intellectual-property milestones, moving from depressed valuations toward renewed investor interest in its radiopharmaceutical pipeline. From what I see, this kind of move often follows clear clinical progress in the sector.
Drivers Behind the Recent 30-Day Advance
The main catalyst was the presentation of first-in-human data for ATNM-400 at the 39th Annual Congress of the European Association of Nuclear Medicine (EANM 2026) in Vienna. The company shared encouraging initial results from its Phase 1 dose-escalation study in metastatic castration-resistant prostate cancer, including a favorable early safety profile, sustained tumor retention, and no dose-limiting toxicities in the initial cohort, with escalation moving to the next level.
Preclinical results were also presented, showing ATNM-400 activity across lung, colorectal, and ovarian cancer models and highlighting the program’s broader potential. These updates triggered heavy trading volume and a double-digit intraday move in mid-October. Analyst commentary added support, with firms reiterating Buy ratings and price targets of $3.00 to $5.00. In early November, an ASH 2026 abstract on long-term safety results for Actimab-A combined with CLAG-M in relapsed or refractory AML provided an additional hematology-focused catalyst.
Broader Factors Supporting Quarterly Performance
Beyond the October data, the three-month advance reflects meaningful progress across the company’s story. In August, Actinium announced advances in its Actimab-A intellectual-property and manufacturing programs and confirmed that NYSE Regulation had accepted its compliance plan, allowing the stock to remain listed on NYSE American through November 2027. This step removed a notable overhang for investors.
New patent allowances were also announced covering Actimab-A and Iomab-ACT programs, strengthening protection in both hematologic and cell-therapy conditioning areas. Together, these developments pointed to progress in both the solid-tumor and hematology pipelines, encouraging a re-rating from the multi-month lows seen in early August as investors positioned ahead of expected clinical milestones from the fourth quarter of 2026 into 2027.
Key Events on the Horizon
Several catalysts could influence ATNM’s path in the coming months. The ASH 2026 Annual Meeting in December will offer a fuller look at the Actimab-A long-term safety and tolerability data, with the program advancing toward a Phase 2/3 trial in AML. Continued dose-escalation updates from the ATNM-400 Phase 1 study will also be watched closely as the company seeks a recommended Phase 2 dose.
Progress against the NYSE American compliance plan, ongoing patent activity, and any preclinical or partnership updates remain worth monitoring. As a clinical-stage company with limited revenue, financing and cash runway continue to be relevant factors, along with shifts in radiopharmaceutical sector sentiment or regulatory conditions. These are areas to watch rather than assurances of future results. I’m watching this closely as the data readouts unfold.
Using Tickeron AI Tools for Deeper Analysis
In my own research process, I often turn to Tickeron’s AI Trading Bots to test systematic approaches alongside traditional fundamental review. The platform offers a range of automated strategies across different timeframes and risk profiles, which can help identify patterns in momentum or sector rotation that complement clinical catalyst tracking. It has become a practical addition when evaluating names like ATNM that move on data events.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
ATNM in upward trend: 10-day moving average crossed above 50-day moving average on October 20, 2026
The 10-day moving average for ATNM crossed bullishly above the 50-day moving average on October 20, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 13 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 87%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
ATNM moved above its 50-day moving average on October 16, 2026 date and that indicates a change from a downward trend to an upward trend.
The 50-day moving average for ATNM moved above the 200-day moving average on October 20, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Following a +23.89% 3-day Advance, the price is estimated to grow further. Considering data from situations where ATNM advanced for three days, in 165 of 230 cases, the price rose further within the following month. The odds of a continued upward trend are 72%.
Bearish Trend Analysis
The 10-day RSI Indicator for ATNM moved out of overbought territory on October 26, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 22 similar instances where the indicator moved out of overbought territory. In 20 of the 22 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.
The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ATNM as a result. In 77 of 94 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 82%.
The Moving Average Convergence Divergence Histogram (MACD) for ATNM turned negative on November 05, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 51 similar instances when the indicator turned negative. In 40 of the 51 cases the stock turned lower in the days that followed. This puts the odds of success at 78%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ATNM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
ATNM broke above its upper Bollinger Band on October 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for ATNM entered a downward trend on October 19, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 8 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 22 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. ATNM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 74 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.484) is normal, around the industry mean (3.498). P/E Ratio (4.086) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (1.105) is also within normal values, averaging (440.869).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ATNM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a biopharmaceutical company developing targeted payload immunotherapeutic for the treatment of advanced cancers
Industry Biotechnology
Advertisement